Low-dose nesiritide improves renal function in heart failure patients following acute myocardial infarction |
| |
Authors: | Qiang Zhao Tong-Guo Wu Yi Lin Biao Li Jing-Yun Luo Le-Xin Wang |
| |
Institution: | (1) Department of Experimental Surgery and Surgical Research “N.S.Christeas”, University of Athens, Medical School, 15B Agiou Thoma Street, 11527 Athens, Greece; |
| |
Abstract: | This study was designed to investigate the effect of low-dose nesiritide on renal function and major cardiac events in patients
with acute decompensated heart failure following acute myocardial infarction. Sixty patients were randomized into nesiritide
(loading dose 0.5 μg/kg, maintenance dose 0.0075 μg/kg/min) and nitroprusside groups. Compared with the nitroprusside group,
the nesiritide group had a greater heart rate reduction (P < 0.05), higher 24 h urine volume (P < 0.001), and more significant alleviation in dyspnea (P < 0.001). The prevalence of hypotension in the nesiritide group was lower than in the nitroprusside group (7.4% vs 28.5%,
P < 0.05). The nesiritide group had a greater reduction in serum noradrenaline, angiotensin II, aldosterone, endothelin, and
N-terminal prohormone brain natriuretic peptide (all P < 0.01). The mean serum creatinine in the nesiritide group was reduced (109.4 ± 26.6 vs 102.8 ± 21.6 μmol/l, P < 0.01), whereas it remained unchanged in the nitroprusside group (106.8 ± 20 vs 106.0 ± 19.2 μmol/l, P > 0.05). The rehospitalization or mortality rate was similar between the two groups 3 months after the therapy (P > 0.05). We conclude that low-dose nesiritide is more effective in suppressing the activation of the sympathetic and renin-angiotensin
systems. It also improves the clinical symptoms and enhances renal function, but its effect on hospital readmission or mortality
rate needs further investigation. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|